Expertise
DIVERSA develops advanced nanodelivery technologies for RNA and biomolecule‑based therapeutics. Beyond its own therapeutic developments, DIVERSA positions itself as a technology‑enabling partner for pharma and biotech.
Author
María de la Fuente
CEO/CSO
DIVERSA TECHNOLOGIES SL
Santiago de Compostela, Spain
8 profile visits
I lead DIVERSA, turning advanced delivery science into clinical nanomedicines through patented sphingolipid nanotechnology and strong translational expertise. We help advance high‑value programs by overcoming delivery bottlenecks.
My organisation
DIVERSA positions itself as a strategic technology‑enabling partner for pharma and biotech companies developing RNA and biomolecule‑based therapeutics in indications where delivery is the primary bottleneck. The company collaborates closely with partners to address delivery challenges across the development continuum, supporting the optimization of formulation, localization, reproducibility and translational robustness of assets. Designed for challenging tissue environments where conventional systems struggle, DIVERSA’s patented Sphingolipid Nanoparticle (SNP) and Sphingolipid Nanoemulsion (SN) platforms deliver both technical differentiation and a strong, defensible Freedom to Operate (FTO), offering partners a strategically clean alternative to the densely patented LNP landscape. This positioning enables pharma and biotech companies to advance high‑value RNA and biotechnology programs with reduced IP risk, lower dependency on third‑party platforms and greater flexibility in co‑development, licensing and long‑term pipeline strategy.
About me
María de la Fuente, co-founder and CEO/CSO of DIVERSA, has a Ph.D. in pharmaceutical technology, nanotechnology, and drug administration from the University of Santiago de Compostela. In addition, she has training in management, direction, and entrepreneurship, highlighting his participation in the Senior Management Program of Research, Innovation and Technology Transfer Institutions of the University of Navarra (IESE), the program in Business Leadership Development and Team Management from ESADE (Ramon Llull University), and the Caixaimpulse program, taught by the Barcelona School of Management, for knowledge transfer and entrepreneurship. She has completed an Executive MBA (Galicia Business School). She has also participated in Bootcamps such as Oncostars and PANACEA in Oxford and received additional training in programs from the Xunta de Galicia (GAIN -Oxentia- and ACIS), as well as other Europeans (EIT Health). Her previous activity in technology transfer is related to the license to Advancell SL of several patents, being co-inventor of them, and to the participation in knowledge transfer during her stay in the SOP-UCL. Concerning her professional experience, María is the head of the Nano-Oncology and Translational Therapeutics group at the Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital, and has experience in leadership, teamwork, and resource management. From her professional independence as Principal Investigator, she has raised more than 4.5M€ of public and private funds in competitive calls, of which 0.6M€ have been specific for technology transfer.